Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 4,023 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Substance Abuse
Interventions: computer-assisted Screening & Brief Advice, computer-assisted Screening & Brief Advice Plus; Behavioral
Lead sponsor: Treatment Research Institute; Other
Eligibility: 12 Years to 18 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Bioavailability, B-cell Lymphoid Cancer
Interventions: Treatment A- Part 1, Treatment B- Part 1, Treatment C - Part 1, Treatment D- Part 1, Treatment A-Part 2, Treatment B - Part 2, Treatment C - Part 2, Treatment D - Part 2; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers
Interventions: ASP1617, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Glendale, California

Conditions: Sarcoma, Alveolar Soft Part
Interventions: Cediranib, Sunitinib, Prochlorperazine, Promethazine, Benzodiazepine, Filgrastim, Sargramostim, Lomotil, Loperamide, Vitamin B6, Aquaphor, Acetaminophen, Levothyroxine, Warfarin; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years to 120 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Phase 1 Pharmacodynamic Study
Interventions: Oral rsCT tablet, Oral Placebo Tablet, Fortical (rsCT) nasal spray; Drug
Lead sponsor: Tarsa Therapeutics, Inc.; Industry
Eligibility: 45 Years to 70 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Metastatic Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions: DZ-002 - 5 mg/kg, 6 mg/kg, or 7 mg/kg; Drug
Lead sponsor: Hoag Memorial Hospital Presbyterian; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Colorectal Cancer, Colorectal Carcinoma, Liver Metastases
Interventions: SIR-Spheres yttrium-90 microspheres, Systemic chemotherapy (FOLFOX); Device · Drug
Lead sponsor: Sirtex Medical; Industry
Eligibility: 18 Years and older
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 21
States / cities: Scottsdale, Arizona • Duarte, California • North Miami Beach, Florida + 16 more

Conditions: Hemophilia A
Interventions: PEGylated Recombinant Factor VIII, ITI; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: Up to 5 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 20
States / cities: Phoenix, Arizona • Cupertino, California • Oakland, California + 17 more

Conditions: Desmoid, Desmoid Tumor
Interventions: AL102, Placebo; Drug · Other
Lead sponsor: Immunome, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 23
States / cities: Pheonix, Arizona • Duarte, California • Santa Monica, California + 17 more

Conditions: Advanced Solid Tumors
Interventions: ASP2074; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 8
States / cities: Sacramento, California • Iowa City, Iowa • Detroit, Michigan + 5 more

Conditions: Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer, Colorectal Cancer, Breast Cancer
Interventions: Andecaliximab, Gemcitabine, Nab-paclitaxel, Carboplatin, Pemetrexed, Leucovorin, Oxaliplatin, 5-FU, Bevacizumab, Irinotecan, Paclitaxel; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 18
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 14 more

Conditions: HIV Medication Adherence, Methamphetamine Use, Sexual Risk, Poly-substance Use, HIV Infections
Interventions: Motivational Interviewing + Cognitive Behavioral Skills Training, Education Attention Control; Behavioral
Lead sponsor: Hunter College of City University of New York; Other
Eligibility: 18 Years and older · Male only
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Solid Tumor, Adult
Interventions: eFT226, Sotorasib, Fulvestrant, Abemaciclib, Trastuzumab; Drug
Lead sponsor: Effector Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 14
States / cities: Los Angeles, California • Newport Beach, California • Palo Alto, California + 10 more

Conditions: Hematologic Malignancies
Interventions: StemEx; Biological
Lead sponsor: Loyola University; Other
Eligibility: 55 Years to 73 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Healthy Adult Participants, Synaptic Plasticity
Interventions: PET Imaging Scan using [11C]UCB-J; Radiation
Lead sponsor: Beatriz Luna; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Unresectable Metastatic Colorectal Cancer
Interventions: ABBV-400, Bevacizumab, Folinic Acid, Fluorouracil, Irinotecan; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 22
States / cities: Phoenix, Arizona • Springdale, Arkansas • Duarte, California + 15 more

Conditions: Philadelphia Chromosome Negative, B Cell Acute Lymphoblastic Leukemia (B-ALL), B-ALL
Interventions: Nutrition Intervention, Exercise intervention; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Moderate to Severe Atopic Dermatitis
Interventions: ISB 830 - Part 1 Group 1, ISB 830 - Part 1 Group 2, ISB 830 - Part 1 Group 3, Placebo - Part 1 Group 4, ISB 830 - Part 2 Group 5, Placebo - Part 2 Group 6; Drug
Lead sponsor: Ichnos Sciences SA; Industry
Eligibility: 18 Years and older
Enrollment: 462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 34
States / cities: Birmingham, Alabama • Clovis, California • Rolling Hills Estates, California + 29 more

Conditions: CLARITHROMYCIN/DILTIAZEM [VA Drug Interaction]
Interventions: Clarithromycin XL, 2% Diltiazem; Drug
Lead sponsor: Ventrus Biosciences, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Paramus, New Jersey

Conditions: Mental Health Wellness 1, Loneliness
Interventions: Contemplative dyad meditation, Fast friends; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 35 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions: PF-08046876, Pembrolizumab, Cisplatin, Carboplatin; Drug · Combination Product
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 21
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 11 more

Conditions: Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM)
Interventions: Lymphodepleting chemotherapy: Cyclophosphamide, Lymphodepleting chemotherapy: Bendamustine, Lymphodepleting chemotherapy: Fludarabine, Lisocabtagene Maraleucel, Axicabtagene Ciloleucel, Ciltacabtagene Autoleucel, Low-Dose Total Body Irradiation; Drug · Other · Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced MDS, Acute Myeloid Leukemia
Interventions: ARRY-520, KSP(Eg5) inhibitor; intravenous; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 17 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Atlanta, Georgia • Houston, Texas

Conditions: Vasopressin Deficiency
Interventions: Intranasal Oxytocin (IN-OXT) 6 IU single dose, Intranasal Oxytocin (IN-OXT) 6 IU repeat dose, Placebo repeat dose, Intranasal Oxytocin (IN-OXT) 24 IU single dose, Placebo single dose; Drug
Lead sponsor: Elizabeth Austen Lawson; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Advancing Adolescent Screening and Brief Intervention Protocols in Primary Care Settings

A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food Effect

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

A Study of Oral Calcitonin Given at Night to Healthy Postmenopausal Women

Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A

A Study of AL102 in Patients With Progressing Desmoid Tumors

A Study of ASP2074 in Adults With Solid Tumors

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

Intervention Targeting Medication Adherence and Methamphetamine Use in HIV Positive Men (ACE)

Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

Umbilical Cord Transplantation for the Elderly Population

Effects of Adolescent Synaptic Pruning

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)

Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis

Study to Evaluate the Interaction Potential of Clarithromycin XL on Diltiazem Hydrochloride Cream 2% in Healthy Subjects

The Impact of Dyad Exercises on Well-being and Connection in Young Adults

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia

Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency